IRIS Accounts Production v25.1.3.33 08350786 director 1.8.23 31.1.25 31.1.25 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh083507862023-07-31083507862025-01-31083507862023-08-012025-01-31083507862022-01-31083507862022-02-012023-07-31083507862023-07-3108350786ns15:EnglandWales2023-08-012025-01-3108350786ns14:PoundSterling2023-08-012025-01-3108350786ns10:Director12023-08-012025-01-3108350786ns10:PrivateLimitedCompanyLtd2023-08-012025-01-3108350786ns10:SmallEntities2023-08-012025-01-3108350786ns10:AuditExemptWithAccountantsReport2023-08-012025-01-3108350786ns10:SmallCompaniesRegimeForDirectorsReport2023-08-012025-01-3108350786ns10:SmallCompaniesRegimeForAccounts2023-08-012025-01-3108350786ns10:FullAccounts2023-08-012025-01-3108350786ns10:OrdinaryShareClass12023-08-012025-01-3108350786ns10:RegisteredOffice2023-08-012025-01-3108350786ns5:CurrentFinancialInstruments2025-01-3108350786ns5:CurrentFinancialInstruments2023-07-3108350786ns5:ShareCapital2025-01-3108350786ns5:ShareCapital2023-07-3108350786ns5:RetainedEarningsAccumulatedLosses2025-01-3108350786ns5:RetainedEarningsAccumulatedLosses2023-07-3108350786ns5:ComputerEquipment2023-08-012025-01-3108350786ns5:FurnitureFittings2023-07-3108350786ns5:ComputerEquipment2023-07-3108350786ns5:FurnitureFittings2023-08-012025-01-3108350786ns5:FurnitureFittings2025-01-3108350786ns5:ComputerEquipment2025-01-3108350786ns5:FurnitureFittings2023-07-3108350786ns5:ComputerEquipment2023-07-3108350786ns10:OrdinaryShareClass12025-01-31
REGISTERED NUMBER: 08350786 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD

1 AUGUST 2023 TO 31 JANUARY 2025

FOR

PRIORY PHARMA CONSULTING LTD

PRIORY PHARMA CONSULTING LTD (REGISTERED NUMBER: 08350786)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 AUGUST 2023 TO 31 JANUARY 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Report of the Accountants 6

PRIORY PHARMA CONSULTING LTD

COMPANY INFORMATION
FOR THE PERIOD 1 AUGUST 2023 TO 31 JANUARY 2025







DIRECTOR: Mrs A C Jackson





REGISTERED OFFICE: 24 Priory Hill
Dover
Kent
CT17 0AA





REGISTERED NUMBER: 08350786 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

PRIORY PHARMA CONSULTING LTD (REGISTERED NUMBER: 08350786)

BALANCE SHEET
31 JANUARY 2025

2025 2023
Notes £    £   
CURRENT ASSETS
Debtors 5 - 16,690
Cash at bank 229,553 265,952
229,553 282,642
CREDITORS
Amounts falling due within one year 6 9,044 44,359
NET CURRENT ASSETS 220,509 238,283
TOTAL ASSETS LESS CURRENT
LIABILITIES

220,509

238,283

CAPITAL AND RESERVES
Called up share capital 7 1 1
Retained earnings 220,508 238,282
SHAREHOLDERS' FUNDS 220,509 238,283

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 January 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 June 2025 and were signed by:





Mrs A C Jackson - Director


PRIORY PHARMA CONSULTING LTD (REGISTERED NUMBER: 08350786)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD 1 AUGUST 2023 TO 31 JANUARY 2025

1. STATUTORY INFORMATION

Priory Pharma Consulting Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Financial Statements are presented in round pounds sterling £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates and value added tax.

Turnover represents invoiced sales of services, net of value added tax. The sales are recognised once the service has been completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.
It is the Company's policy to capitalise items with an estimated useful life in excess of two years, and for amounts in excess of £250.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

PRIORY PHARMA CONSULTING LTD (REGISTERED NUMBER: 08350786)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 AUGUST 2023 TO 31 JANUARY 2025

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 (2023 - 1 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Computer
fittings equipment Totals
£    £    £   
COST
At 1 August 2023 1,300 - 1,300
Additions - 930 930
Disposals (1,300 ) (930 ) (2,230 )
At 31 January 2025 - - -
DEPRECIATION
At 1 August 2023 1,300 - 1,300
Charge for period - 128 128
Eliminated on disposal (1,300 ) (128 ) (1,428 )
At 31 January 2025 - - -
NET BOOK VALUE
At 31 January 2025 - - -
At 31 July 2023 - - -

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2023
£    £   
Trade debtors - 16,690

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2023
£    £   
Tax 4,041 23,771
Social security and other taxes 145 7
VAT - 8,898
Other creditors - 10,000
Directors' current accounts 3,029 434
Accrued expenses 1,829 1,249
9,044 44,359

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2023
value: £    £   
1 Ordinary £1 1 1

PRIORY PHARMA CONSULTING LTD (REGISTERED NUMBER: 08350786)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE PERIOD 1 AUGUST 2023 TO 31 JANUARY 2025

8. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

During the year, the following Loan Account subsisted;

Directors Loan Account
A member or key management personnel

During the year, the Director advanced the Company £3,052 (2023: £1,449)

During the year, the Company repaid the Director £457 (2023: £8,965)

As at the year end, the Company owed the Director £3,029 (2023: £434)

The loan is interest free and repayable upon demand.

PRIORY PHARMA CONSULTING LTD

REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
PRIORY PHARMA CONSULTING LTD

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the period ended 31 January 2025 set out on pages one to nine and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


Date: .............................................